Ondansetron Basi

Ondansetron, the active ingredient in Ondansetron Basi, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for systemic use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and paediatric patients. GNH USA supplies Ondansetron Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetron Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Basi is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps maintain patient comfort during radiotherapy. - Post‑operative nausea and vomiting: lowers the incidence of nausea after surgical procedures. - Pregnancy‑associated nausea (off‑label): may be considered when benefits outweigh risks, under specialist guidance. - Hyper‑emesis gravidarum (off‑label): used in severe cases resistant to first‑line therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement reduction. - Diarrhoea: loose stools in a minority of patients. - Fatigue: general tiredness reported. - Dizziness: transient light‑headedness. - Injection site pain (if administered parenterally): mild discomfort at the site.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals. - Neuroleptic malignant‑like reactions: very rare, characterized by fever and rigidity. - Vision changes: blurred vision or visual disturbances.

Ondansetron should be used with caution in patients with known cardiac conduction abnormalities or electrolyte disturbances.

- Cardiac monitoring: obtain baseline ECG in patients at risk for QT prolongation. - Electrolyte assessment: correct potassium, magnesium and calcium before initiation. - Hepatic impairment: adjust dosing in severe liver disease. - Drug interactions: review concomitant medications that affect QT interval. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated. - Store at below 25°C: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medicines that influence cardiac rhythm or serotonin pathways.

Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on cardiac repolarisation. - Serotonergic drugs (e.g., tramadol, linezolid, SSRIs): raise potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure. - Diuretics causing electrolyte loss: heighten QT‑prolongation risk. - Other anti‑emetics (e.g., granisetron, dolasetron): overlapping mechanisms, monitor efficacy. - Oral contraceptives: possible slight reduction in hormonal efficacy.